HKSE - Delayed Quote HKD

RemeGen Co., Ltd. (9995.HK)

Compare
13.280
-0.460
(-3.35%)
At close: January 28 at 12:08:04 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,076,130.000
1,076,130.000
767,775.000
1,423,902.000
--
Cost of Revenue
253,136.000
253,136.000
269,939.000
67,163.000
--
Gross Profit
822,994.000
822,994.000
497,836.000
1,356,739.000
--
Operating Expense
2,325,340.000
2,325,340.000
1,551,915.000
1,053,655.000
637,242.000
Operating Income
-1,502,346.000
-1,502,346.000
-1,054,079.000
303,084.000
-637,242.000
Net Non Operating Interest Income Expense
5,052.000
5,052.000
54,786.000
38,025.000
-27,571.000
Pretax Income
-1,511,229.000
-1,511,229.000
-998,830.000
276,258.000
-697,821.000
Net Income Common Stockholders
-1,511,229.000
-1,511,229.000
-998,830.000
276,258.000
-697,821.000
Diluted NI Available to Com Stockholders
-1,511,229.000
-1,511,229.000
-998,830.000
276,258.000
-697,821.000
Basic EPS
-2.80
--
-1.88
0.57
-1.71
Diluted EPS
-2.80
--
-1.88
0.57
-1.71
Basic Average Shares
538,914.230
--
530,120.137
487,443.301
408,148.548
Diluted Average Shares
539,873.390
--
531,154.544
487,443.301
408,148.548
Total Expenses
2,578,476.000
2,578,476.000
1,821,854.000
1,120,818.000
637,242.000
Net Income from Continuing & Discontinued Operation
-1,511,229.000
-1,511,229.000
-998,830.000
276,258.000
-697,821.000
Normalized Income
-1,506,977.000
-1,506,977.000
-999,823.000
276,599.000
-697,779.000
Interest Income
28,143.000
28,143.000
61,543.000
43,348.000
1,655.000
Interest Expense
23,091.000
23,091.000
6,757.000
5,323.000
29,226.000
Net Interest Income
5,052.000
5,052.000
54,786.000
38,025.000
-27,571.000
EBIT
-1,488,138.000
-1,488,138.000
-992,073.000
281,581.000
-668,595.000
EBITDA
-1,247,859.000
-1,247,859.000
-805,702.000
402,053.000
-590,929.000
Reconciled Cost of Revenue
253,136.000
253,136.000
269,939.000
67,163.000
--
Reconciled Depreciation
240,279.000
240,279.000
186,371.000
120,472.000
77,666.000
Net Income from Continuing Operation Net Minority Interest
-1,511,229.000
-1,511,229.000
-998,830.000
276,258.000
-697,821.000
Total Unusual Items Excluding Goodwill
-4,252.000
-4,252.000
993.000
-341.000
-42.000
Total Unusual Items
-4,252.000
-4,252.000
993.000
-341.000
-42.000
Normalized EBITDA
-1,243,607.000
-1,243,607.000
-806,695.000
402,394.000
-590,887.000
12/31/2020 - 11/9/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1167.HK JACOBIO-B
1.420
-3.40%
 
9926.HK Akeso, Inc.
60.850
+1.76%
 
PLRX Pliant Therapeutics, Inc.
10.66
-0.74%
 
ETNB 89bio, Inc.
9.64
+10.42%
 
SMMT Summit Therapeutics Inc.
22.36
+3.33%
 
IOVA Iovance Biotherapeutics, Inc.
6.21
+2.31%
 
AKRO Akero Therapeutics, Inc.
55.36
+2.52%
 
MRNA Moderna, Inc.
41.04
+0.79%